Patents by Inventor Peter Jones

Peter Jones has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20240239515
    Abstract: A method of manufacturing an aircraft assembly is disclosed including forming a first tension hole in a first aircraft component and a second tension hole in a second aircraft component. The first and second aircraft components are positioned relative to each other such that the first tension hole at least partially overlies the second tension hole, to define a pair of tension holes. The first aircraft component is secured relative to the second aircraft component by providing a first fastener between the first tension hole and the second tension hole of the pair of tension holes. A first shear hole is formed in the first aircraft component and a second shear hole is formed in the second aircraft component. The first shear hole is axially aligned with the second shear hole, to define a pair of shear holes.
    Type: Application
    Filed: January 11, 2024
    Publication date: July 18, 2024
    Inventors: Peter KELLY, Timothy JONES, Julien LAVERNE
  • Publication number: 20240197200
    Abstract: A device includes a sensor and a control portion. The sensor is securable to a patient to provide a sensor signal. The sensor is to sense changes in acceleration indicative of respiration of the patient. The control portion is to determine a midpoint of each respiratory phase of the patient based on the sensor signal.
    Type: Application
    Filed: June 9, 2022
    Publication date: June 20, 2024
    Applicant: INSPIRE MEDICAL SYSTEMS, INC.
    Inventors: Christopher Thorp, David Dieken, Nicholas Nesbitt, John Rondoni, James Manne-Nicholas, Ross Peter Jones, Mark Schatza, Christopher Nicholas Warwick, Jonathan Tudor Stone, Frederico CANAS DE MATOS E OLIVEIRA RIBEIRO
  • Patent number: 12007744
    Abstract: A plurality of system control devices respectively include network interfaces for communicating with each other via a network. One of the plurality of system control devices functions as a master system control device, and the remaining system control devices function as slave system control devices. The master system control device transmits a control command to the slave system control devices by means of the network interface. The slave system control devices receive the control command by means of the network interfaces and supply an operation command to abatement devices in accordance with the control command. When unable to communicate with the master system control device, the slave system control devices either function as master system control devices or enter stand-alone operation mode.
    Type: Grant
    Filed: August 5, 2019
    Date of Patent: June 11, 2024
    Assignees: Edwards Japan Limited, Edwards Limited
    Inventors: Kobayashi Kenichiro, Adrian Fisher, Christopher Peter Jones, Philip Carr
  • Publication number: 20240187123
    Abstract: A method of implementing a stretched single optical communication span includes receiving one or more optical signals from an optical fiber span having high loss; adding a pilot signal to the one or more optical signals, subsequent to the receiving; and amplifying the one or more optical signals and the pilot signal with a pre-amplifier that is an Erbium Doped Fiber Amplifier (EDFA). Advantageously, the stretched single span operates below a Hazard 1M environment. A node in a stretched single optical communication span includes an optical multiplexer connected to an optical fiber span having high and a pilot signal, and configured to output a combination of one or more optical signals from the optical fiber span and the pilot signal; and a pre-amplifier that is an EDFA configured to receive the output of the optical multiplexer and provide amplification of the one or more optical signals and the pilot signal.
    Type: Application
    Filed: December 6, 2022
    Publication date: June 6, 2024
    Inventors: Kevan Peter Jones, Vipul Bhatnagar, Marco Gaudet, Francois Maurice Rheal Charron
  • Publication number: 20240132455
    Abstract: The present disclosure relates to certain (2S)—N-[(1S)-1-cyano-2-phenylethyl]-1,4-oxazepane-2-carboxamide compounds (including pharmaceutically acceptable salts thereof), that inhibit dipeptidyl peptidase 1 (DPP1) activity, to their utility in treating and/or preventing clinical conditions including respiratory diseases, such as asthma and chronic obstructive pulmonary disease (COPD), to their use in therapy, to pharmaceutical compositions containing them and to processes for preparing such compounds.
    Type: Application
    Filed: December 8, 2023
    Publication date: April 25, 2024
    Inventors: Hans Roland LÖNN, Stephen Connolly, Steven Swallow, Staffan Po Karlsson, Carl-Johan Aurell, John Fritiof PONTÉN, Kevin James Doyle, Amanda Jane VAN DE POËL, Graham Peter Jones, David Wyn Watson, Jacqueline Anne MACRITCHIE, Nicholas John Palmer
  • Patent number: 11927807
    Abstract: According to various aspects of the present disclosure, an apparatus is provided. In an aspect, the apparatus includes an optical transceiver having a first port, a second port and an optical switch coupled to the first port and the second port. The optical switch is switchable between a unidirectional port operation mode and a bidirectional port operation mode. When the optical switch is in the unidirectional port operation mode, the first port is configured to send a first optical signal, and the second port configured to receive a second optical signal. When the optical switch is in the bidirectional port operation mode, the first port configured to send the first optical signal and receive the second optical signal, and the second port configured to receive a third optical signal and not send the first signal.
    Type: Grant
    Filed: November 29, 2022
    Date of Patent: March 12, 2024
    Assignee: Juniper Networks, Inc.
    Inventors: Kevan Peter Jones, Robert William Keys
  • Patent number: 11884672
    Abstract: The disclosure provides compounds useful for treating alpha-1 antitrypsin deficiency (AATD), according to formula (I): tautomers thereof, pharmaceutically acceptable salts of the compounds, pharmaceutically acceptable salts of the tautomers, deuterated derivatives of the compounds, deuterated derivatives of the tautomers, and deuterated derivatives of the salts, solid forms of those compounds and processes for making those compounds.
    Type: Grant
    Filed: May 13, 2020
    Date of Patent: January 30, 2024
    Assignee: Vertex Pharmaceuticals Incorporated
    Inventors: Upul Keerthi Bandarage, Cavan McKeon Bligh, Diane Boucher, Michael John Boyd, Michael Aaron Brodney, Michael Philip Clark, Veronique Damagnez, Lev Tyler Dewey Fanning, Robert Francis Fimognari, Gabrielle Simone Fleming, Kevin James Gagnon, Pedro Manuel Garcia Barrantes, Robert Daniel Giacometti, Simon Giroux, Ronald Lee Grey, Jr., Samantha Guido, Amy Beth Hall, Sarah Carol Hood, Dennis James Hurley, Mac Arthur Johnson, Jr., Peter Jones, Sarathy Kesavan, Mei-Hsiu Lai, Siying Liu, Adam Looker, Brad Maxwell, John Patrick Maxwell, Ales Medek, Philippe Marcel Nuhant, Kirk Alan Overhoff, Setu Roday, Stefanie Roeper, Steven M. Ronkin, Rupa Sawant, Yi Shi, Muna Shrestha, Marisa Sposato, Kathy Stavropoulos, Rebecca Jane Swett, Timothy Lewis Tapley, Qing Tang, Stephen Thomson, Jinwang Xu, Mariam Zaky, Kevin Michael Cottrell
  • Patent number: 11814359
    Abstract: The present disclosure relates to certain (2,S)-N-[(1,S)-1-cyano-2-phenylethyl]-1,4-oxazepane-2-carboxamide compounds (including pharmaceutically acceptable salts thereof), that inhibit dipeptidyl peptidase 1 (DPP1) activity, to their utility in treating and/or preventing clinical conditions including respiratory diseases, such as asthma and chronic obstructive pulmonary disease (COPD), to their use in therapy, to pharmaceutical compositions containing them and to processes for preparing such compounds.
    Type: Grant
    Filed: September 10, 2022
    Date of Patent: November 14, 2023
    Assignee: AstraZeneca AB
    Inventors: Hans Roland Lönn, Stephen Connolly, Steven Swallow, Staffan Po Karlsson, Carl-Johan Aurell, John Fritiof Pontén, Kevin James Doyle, Amanda Jane Van De Poël, Graham Peter Jones, David Wyn Watson, Jacqueline Anne Macritchie, Nicholas John Palmer
  • Publication number: 20230339915
    Abstract: Novel compounds, compositions, and methods of using and preparing the same, which maybe useful for treating alpha-1 antitrypsin deficiency (AATD).
    Type: Application
    Filed: April 2, 2021
    Publication date: October 26, 2023
    Inventors: Simon GIROUX, Michael Philip CLARK, Qing TANG, Philippe Marcel NUHANT, Peter JONES, David MESSERSMITH, Upul Keerthi BANDARAGE, Kevin Michael COTTRELL, Michael Aaron BRODNEY, Gabrielle Simone FLEMING, Jian WANG, Jinwang XU, Kevin Brett DANIEL, Michael John BOYD, Mark A. MORRIS, Nathan D. WAAL, Philip Noel COLLIER, Sarathy KESAVAN, Steven M. RONKIN, Hongbo DENG, Diane Marie BOUCHER, Lev T.D. FANNING, Amy B. HALL, Dennis James HURLEY, Mac Arthur JOHNSON, Jr., John Patrick MAXWELL, Rebecca Jane SWETT, Timothy Lewis TAPLEY, Stephen A. THOMSON, Veronique DAMAGNEZ
  • Patent number: 11773069
    Abstract: The present disclosure relates to certain (2S)-N-[(1S)-1-cyano-2-phenylethyl]-1,4-oxazepane-2-carboxamide compounds (including pharmaceutically acceptable salts thereof), that inhibit dipeptidyl peptidase 1 (DPP1) activity, to their utility in treating and/or preventing clinical conditions including respiratory diseases, such as asthma and chronic obstructive pulmonary disease (COPD), to their use in therapy, to pharmaceutical compositions containing them and to processes for preparing such compounds.
    Type: Grant
    Filed: September 9, 2022
    Date of Patent: October 3, 2023
    Assignee: AstraZeneca AB
    Inventors: Hans Roland Lönn, Stephen Connolly, Steven Swallow, Staffan Po Karlsson, Carl-Johan Aurell, John Fritiof Pontén, Kevin James Doyle, Amanda Jane Van De Poël, Graham Peter Jones, David Wyn Watson, Jaqueline Anne Macritchie, Nicholas John Palmer
  • Publication number: 20230294049
    Abstract: Embodiments described herein relate to systems and methods for carbonating a liquid at ambient temperature. The system may include a liquid source; a carbon dioxide source; and a contactor for carbonating the liquid. The contactor may include channels and a sparge for carbonating liquid flowing through the channels. The system may produce a liquid having high levels of carbonation at ambient temperature. The sparge may generate microbubbles or nanobubbles to allow for cost-effective carbonation at ambient temperatures. The bubbles may have an average diameter of 100 ?m or less. The system may carbonate liquid at a rate of 1 gram to 10 grams carbon dioxide per liter.
    Type: Application
    Filed: March 14, 2023
    Publication date: September 21, 2023
    Inventors: John EATON, Mary Katherine MITCHELL, Stephen BROWN, Ross Peter JONES, Charles Frazer KILBY, Laura Saranne KIMPTON, Andrew Robert POTTER
  • Publication number: 20230278969
    Abstract: The present disclosure relates to certain (2S)-N-[(1S)-1-cyano-2-phenylethyl]-1,4-oxazepane-2-carboxamide compounds (including pharmaceutically acceptable salts thereof), that inhibit dipeptidyl peptidase 1 (DPP1) activity, to their utility in treating and/or preventing clinical conditions including respiratory diseases, such as asthma and chronic obstructive pulmonary disease (COPD), to their use in therapy, to pharmaceutical compositions containing them and to processes for preparing such compounds.
    Type: Application
    Filed: September 9, 2022
    Publication date: September 7, 2023
    Inventors: Hans Roland LÖNN, Stephen CONNOLLY, Steven SWALLOW, Staffan PO KARLSSON, Carl-Johan AURELL, John Fritiof PONTÉN, Kevin James DOYLE, Amanda Jane VAN DE POËL, Graham Peter JONES, David Wyn WATSON, Jaqueline Anne MACRITCHIE, Nicholas John PALMER
  • Publication number: 20230265080
    Abstract: Novel compounds, compositions, and methods of using and preparing the same, which may be useful for treating alpha-1 antitrypsin deficiency (AATD).
    Type: Application
    Filed: February 9, 2023
    Publication date: August 24, 2023
    Inventors: Upul Keerthi BANDARAGE, Cavan McKeon BLIGH, Michael John BOYD, Diane M. BOUCHER, Michael Aaron BRODNEY, Veronique DAMAGNEZ, Lev Tyler DEWEY FANNING, Mary Elizabeth ECCLES, Robert Francis FIMOGNARI, JR., Kevin James GAGNON, Pedro M. GARCIA BARRANTES, Simon GIROUX, Ronald Lee GREY, JR., Amy Beth HALL, Sarah Carol HOOD, Dennis James HURLEY, Joshua Kennedy HUSSEY, Mac Arthur JOHNSON, JR., Peter JONES, Sarathy KESAVAN, Adam LOOKER, Brad D. MAXWELL, John Patrick MAXWELL, Ales MEDEK, Mettachit NAVAMAL, Philippe Marcel NUHANT, Setu RODAY, Stefanie ROEPER, Rupa SAWANT, Yi SHI, Rebecca Jane SWETT, Qing TANG, Timothy Lewis TAPLEY, Stephen A. THOMSON, Michael WALDO, Jinwang XU, Kevin Michael COTTRELL
  • Publication number: 20230250071
    Abstract: The present disclosure relates to certain (2S)—N-[(1S)-1-cyano-2-phenylethyl]-1,4-oxazepane-2-carboxamide compounds (including pharmaceutically acceptable salts thereof), that inhibit dipeptidyl peptidase 1 (DPP1) activity, to their utility in treating and/or preventing clinical conditions including respiratory diseases, such as asthma and chronic obstructive pulmonary disease (COPD), to their use in therapy, to pharmaceutical compositions containing them and to processes for preparing such compounds.
    Type: Application
    Filed: April 13, 2023
    Publication date: August 10, 2023
    Inventors: Hans Roland LÖNN, Stephen CONNOLLY, Steven SWALLOW, Staffan Po KARLSSON, Carl-Johan AURELL, John Fritiof PONTÉN, Kevin James DOYLE, Amanda Jane VAN DE POËL, Graham Peter JONES, David Wyn WATSON, Jaqueline Anne MACRITCHIE, Nicholas John PALMER
  • Patent number: 11680049
    Abstract: The present disclosure relates to certain (2S)—N-[(1S)-1-cyano-2-phenylethyl]-1,4-oxazepane-2-carboxamide compounds (including pharmaceutically acceptable salts thereof), that inhibit dipeptidyl peptidase 1 (DPP1) activity, to their utility in treating and/or preventing clinical conditions including respiratory diseases, such as asthma and chronic obstructive pulmonary disease (COPD), to their use in therapy, to pharmaceutical compositions containing them and to processes for preparing such compounds.
    Type: Grant
    Filed: September 15, 2022
    Date of Patent: June 20, 2023
    Assignee: AstraZeneca AB
    Inventors: Hans Roland Lönn, Stephen Connolly, Steven Swallow, Staffan Po Karlsson, Carl-Johan Aurell, John Fritiof Pontén, Kevin James Doyle, Amanda Jane Van De Poël, Graham Peter Jones, David Wyn Watson, Jaqueline Anne Macritchie, Nicholas John Palmer
  • Patent number: 11673871
    Abstract: The present disclosure relates to certain (2S)-N-[(1S)-1-cyano-2-phenylethyl]-1,4-oxazepane-2-carboxamide compounds (including pharmaceutically acceptable salts thereof), that inhibit dipeptidyl peptidase 1 (DPP1) activity, to their utility in treating and/or preventing clinical conditions including respiratory diseases, such as asthma and chronic obstructive pulmonary disease (COPD), to their use in therapy, to pharmaceutical compositions containing them and to processes for preparing such compounds.
    Type: Grant
    Filed: September 10, 2022
    Date of Patent: June 13, 2023
    Assignee: AstraZeneca AB
    Inventors: Hans Roland Lönn, Stephen Connolly, Steven Swallow, Staffan Po Karlsson, Carl-Johan Aurell, John Fritiof Pontén, Kevin James Doyle, Amanda Jane Van De Poël, Graham Peter Jones, David Wyn Watson, Jaqueline Anne Macritchie, Nicholas John Palmer
  • Patent number: 11673872
    Abstract: The present disclosure relates to certain (2S)—N-[(1S)-1-cyano-2-phenylethyl]-1,4-oxazepane-2-carboxamide compounds (including pharmaceutically acceptable salts thereof), that inhibit dipeptidyl peptidase 1 (DPP1) activity, to their utility in treating and/or preventing clinical conditions including respiratory diseases, such as asthma and chronic obstructive pulmonary disease (COPD), to their use in therapy, to pharmaceutical compositions containing them and to processes for preparing such compounds.
    Type: Grant
    Filed: September 16, 2022
    Date of Patent: June 13, 2023
    Assignee: AstraZeneca AB
    Inventors: Hans Roland Lönn, Stephen Connolly, Steven Swallow, Staffan Po Karlsson, Carl-Johan Aurell, John Fritiof Pontén, Kevin James Doyle, Amanda Jane Van De Poël, Graham Peter Jones, David Wyn Watson, Jaqueline Anne Macritchie, Nicholas John Palmer
  • Patent number: 11667615
    Abstract: The present disclosure relates to certain (2S)-N-[(1S)-1-cyano-2-phenylethyl]-1,4-oxazepane-2-carboxamide compounds (including pharmaceutically acceptable salts thereof), that inhibit dipeptidyl peptidase 1 (DPP1) activity, to their utility in treating and/or preventing clinical conditions including respiratory diseases, such as asthma and chronic obstructive pulmonary disease (COPD), to their use in therapy, to pharmaceutical compositions containing them and to processes for preparing such compounds.
    Type: Grant
    Filed: February 8, 2021
    Date of Patent: June 6, 2023
    Assignee: AstraZeneca AB
    Inventors: Hans Roland Lönn, Stephen Connolly, Steven Swallow, Staffan Po Karlsson, Carl-Johan Aurell, John Fritiof Pontén, Kevin James Doyle, Amanda Jane Van De Poël, Graham Peter Jones, David Wyn Watson, Jaqueline Anne Macritchie, Nicholas John Palmer
  • Patent number: 11664921
    Abstract: Systems and methods for strategizing the insertion and/or removal of a node into and/or out of a network are provided. A system, according to one implementation, includes a processing device and a memory device configured to store a computer program. The computer program includes instructions that, when executed, enable the processing device to configure a Network Element (NE) in a pass-through mode whereby channels are neither added nor dropped to thereby prepare the NE for insertion into or removal from a photonic network. Upon the insertion of the NE into the photonic network or the removal of the NE from the photonic network, the instructions may further enable the processing device to perform a zero configuration procedure for automatically establishing communication along one or more Optical Service Channels (OSCs) and for automatically controlling gain and loss characteristics along one or more fiber links altered by the insertion or removal.
    Type: Grant
    Filed: November 4, 2021
    Date of Patent: May 30, 2023
    Assignee: Ciena Corporation
    Inventors: Kevan Peter Jones, Vipul Bhatnagar, Ross Caird, Bruno Doyle, Marco Gaudet
  • Patent number: D1017465
    Type: Grant
    Filed: September 20, 2021
    Date of Patent: March 12, 2024
    Assignee: Ford Global Technologies, LLC
    Inventors: Max Wolff, Maurizio Tocco, David Dewitt, Andrew Wolton, Nonthawat Kongsari, Siddhartha Kazami, Rohan Satyamurthy, Emily Lai, Luana Teixeira, Peter Jones